Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors. Via Krishan Maggon 
Scoop.it!
Abstract The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufacturing of personalized-adoptive T-cell medicinal products. These include closed system operations, improving process robustness and simplifying work flows, reducing labor intensity by implementing process automation, scalability and cost, as well as appropriate testing and tracking of products, all while maintaining strict adherence to Current Good Manufacturing Practices and regulatory guidelines. A decentralized manufacturing model is proposed, where in the future patients’ cells could be processed at the point-of-care in the hospital. Via Krishan Maggon
Gilbert C FAURE's insight:
OPEN
Krishan Maggon 's curator insight,
March 14, 2015 1:39 PM
Cancer Gene Therapy (2015) 22, 72–78; doi:10.1038/cgt.2014.78; published online 23 January 2015 Towards a commercial process for the manufacture of genetically modified T cells for therapyOPEN A D Kaiser1, M Assenmacher1, B Schröder1, M Meyer1, R Orentas2, U Bethke1and B Dropulic2 1Miltenyi Biotec GmbH, Bergisch Gladbach, Germany2Lentigen Technology Inc., Gaithersburg, MD, USACorrespondence: Dr A Kaiser, Miltenyi Biotec GmbH, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany. E-mail: andrewk@miltenyibiotec.de; B Dropulic, Lentigen Technology Inc., 910 Clopper Road, Gaithersburg, MD, USA. E-mail: boro.dropulic@lentigen.com Received 22 October 2014; Accepted 5 November 2014
Scoop.it!
Unum Therapeutics is a new #immunotherapy #biotech co. The company has technology for re-programming T-cells. http://t.co/1eE4IRugg9 Via Krishan Maggon
Gilbert C FAURE's insight:
UPENN’s approach (as well as Juno’s) involves Chimeric Antigen Receptors (CAR T-cell), comprised of consists of an intracellular T-cell receptor CD3-zeta chain signaling domain that induces T-cell activation, a costimulatory 4-1BB domain that enhances T-cell mediated responses and anti-CD19 antibody fragments that bind to CD19. So, the main difference between Adaptimmune’s approach and UPENN’s is that Adaptimmune uses the T Cell Receptor, itself, and UPENN creates a T Cell Receptor-like molecule using an antibody targeting domain for CD19, which is on the surface of B cells. In clinical studies, 90% patients with acute lymphoblastic leukemia achieved a complete response.
Krishan Maggon 's curator insight,
November 2, 2014 2:12 AM
The company technology has been covered in several scoops here. |
Scoop.it!
The MaxCyte GT® Flow Transfection System is a universal platform technology for rapid, automated loading of CAR (chimeric antigen receptor) mRNA into peripheral blood mononuclear cells using closed-system aseptic processing. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 22, 2015 2:17 AM
Press Release:: MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
Scoop.it!
I recently asked folks for their favorite hot targets in the tumor microenvironment space. Via Krishan Maggon
|
CAR T Cell immunotherapy, TIL, ATC, TCR unpredictable toxicity at AACR 2015